Skip to content

Annual Report 2024/2025

Download the report
Editorial
2025 marks a key milestone for Servier.

The past financial year was marked by major progress in several of our areas of activity. We achieved — and in some cases exceeded — the ambitious targets we had set for ourselves for 2025, and we are on track to deliver on our 2030 ambition.

Read the editorial
President of Servier Olivier Laureau
Our identity

Our value creation model

We are an independent Group with a long-term vision thanks to our governance by a non-profit foundation: the Fondation Internationale de Recherche Servier.

Read more
Our identity

Our stakeholders

One of the keys to our success lies in our ability to meet the expectations of our stakeholders and to collaborate effectively with them.

Discover our stakeholders

Our trajectory that is accelerating

Our trajectory

Paving the way for the future: Servier 2030

Ten years. That is how long Servier has invested to successfully reinvent itself. Operational, organizational, managerial, cultural… This transformation is a springboard and lays the groundwork for the Group’s future: Servier 2030.

Read more
Our trajectory

Innovation with and for patients

We have strengthened our relationship with patients and the organizations that represent them, so as to integrate their voices ever more closely at every stage of the medicine lifecycle. The goal: accelerate the development of tailored therapeutic solutions.

Read more
Our trajectory

A new approach to innovation

We focus on three therapeutic areas, we leverage the power of artificial intelligence and digital, and we are part of collaborative innovation models within global scientific ecosystems.

Read more
Our trajectory

A solid and balanced business model

We are a global leader, ensuring our long-term sustainability through the efficiency and performance of our activities. We are recognized for our expertise across each of our therapeutic areas and in all our markets and our strength is built on an increasingly efficient organization.

Read more
Our trajectory

Men and women as drivers of change

Inspired by the same vocation and carried by strong values, our teams are the key to the Group’s lasting success.

Read more

L’ADN, the media outlet focused on trends and transformations

L’ADN

Servier partners with L’ADN, the media outlet focused on trends and transformations, to decode four major shifts in the global pharmaceutical landscape.

Our impact

Our impact that resonates

All 2024/2025 highlights

Discover
Bio-S, a strategic asset
November 2024
Servier inaugurates Bio-S, its first unit dedicated to the production of biological medicines from its R&D pipeline. Bio-S strengthens Servier’s ability to develop new precision medicines, particularly in the field of oncology.
A global patient council dedicated to cardio-metabolic and venous diseases
December 2024
This Patient Advisory Council brings together 16 members from 15 countries across several continents. Together, they co-develop tools and solutions to overcome barriers to treatment adherence and improve patient care.
70 years of passion, innovation, and commitment.
December 2024
In 2024, we celebrated our 70th anniversary!
Recognizing research on rare pediatric diseases
January 2025
The 8th Pasteur–Weizmann Servier Prize honors Professor Valérie Cormier-Daire for her work on the treatment for rare bone anomalies, opening up new therapeutic perspectives for young patients.
Toward the first quadruple therapy for hypertension
January 2025
Servier has submitted, in 21 European countries, an application for Marketing Authorization for a fixed-dose combination of four antihypertensive agents, with the aim of bringing a new option in an indication where patient needs remain very high.
AI and Data
January 2025
Servier and Google Cloud announced an expanded five-year partnership focused on using AI and generative AI to accelerate the research and development of innovative therapeutic solutions for patients.
Addressing inequalities in pediatric cancer care
February 2025
Servier and a group of partner institutions have joined forces through the “ACT for Children” initiative to improve childhood cancer outcomes in low- and middle-income countries. Together, they are working to strengthen access to treatments, care pathways, healthcare professional training, and support for families.
Servier once again recognized for its culture of engagement
March 2025
We received the Gallup Exceptional Workplace Award for the second consecutive year. 86% of employees recommend Servier as a great place to work.
Signing of a strategic licensing agreement in oncology
March 2025
Servier has signed a global licensing agreement to develop and commercialize a targeted therapy for solid tumors developed by Black Diamond Therapeutics. This partnership highlights our commitment to precision medicine in oncology.
Submission of a new triple-therapy formulation in 18 countries
March 2025
This new prolonged-release formulation represents an important milestone in our commitment to addressing chronic cardiovascular diseases.
Accelerating our industrial development
March 2025
We are inaugurating a new production unit for the active pharmaceutical ingredient of a new synthetic pathway for one of our medicines in venous diseases. Our aim is to secure our production capacity for active ingredients to meet the growing needs of patients worldwide.
A world day for therapeutic adherence
March 2025
Servier, in partnership with 14 institutions, welcomes the creation of the first World Day dedicated to therapeutic adherence, a major public health challenge given that nearly 50% of patients living with chronic diseases do not correctly follow their treatment.
Japan: New marketing authorization in hematology
March 2025
Servier receives marketing authorization in Japan for a targeted therapy in hematology
Servier enters the top 10 of the global PatientView ranking
April 2025
We also reached first place in the oncology category. This progress recognizes our ever-stronger commitment to patients and the organizations that represent them.
Acquisition of a precision therapy for acute leukemias
May 2025
The acquisition from the Chinese biopharmaceutical company BioNova Pharmaceuticals of a potential best-in-class therapy strengthens our leadership in hematological cancers.
A major advance against type 2 diabetes in Brazil
May 2025
Servier has submitted an application in Brazil for a new Single Pill Combination in diabetes. This combination brings together two molecules in a single tablet, simplifying treatment and improving patient adherence.
Partenariat IDEAYA
September 2025
Servier partners with IDEAYA Biosciences to bring a promising treatment to patients with a rare form of eye cancer outside the United States
Acquisition of a potential treatment for Fragile X syndrome
September 2025
We have acquired from the biotech company Kaerus Bioscience a potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorders. This acquisition strengthens our neurology pipeline, in line with our Servier 2030 ambition to target rare neurological diseases.
A new oncology treatment for patients in Europe
September 2025
Following the United States, Australia, Japan, and Brazil, we have received Marketing Authorization from the European Commission for a targeted therapy for patients with a rare form of brain cancer. This illustrates our global commitment to oncology and our ambition to innovate for the benefit of patients living with hard-to-treat cancers.
Our impact

Our financial results 2024/2025

During financial year 2024/2025, we achieved or exceeded most of the objectives we had set for 2025, particularly our revenue and EBITDA targets. We are seeing strong growth in oncology, confirming our commitment to this area and our determination to make our medicines available to an ever-growing number of patients worldwide.

Discover our financial results 2024/2025
Our impact

Committing to a positive and sustainable impact

We are committed to creating value for society as a whole by strengthening our contribution to global health, supporting healthcare systems, and innovating while minimizing our impact on the planet.

Read more
Our impact

Our non-financial results 2024/2025

Measuring our social, societal, and environmental impact makes it possible to assess the Group’s non-financial performance—an essential condition for meeting our sustainability commitments.

Read more

Download the Annual Report 2024/2025

Download the report